Romiplostim

Identification

Name
Romiplostim
Accession Number
DB05332
Description

Romiplostim is a thrombopoiesis stimulating dimer Fc-peptide fusion protein (peptibody) to increase platelet production through activation of the thrombopoietin receptor. The peptibody molecule has two identical single-chain subunits, each one is made up of 269 amino acid residues. Each subunit consists of an IgG1 Fc carrier domain that is covalently attached to a polypeptide sequence that contains two binding domains to interact with thrombopoietin receptor c-Mpl. Each domain consists of 14 amino acids. Interestingly, romiplostim's amino acid sequence is not similar to that of endogenous thrombopoietin. Romiplostim is produced by recombinant DNA technology in Escherichia coli. FDA approved on August 22, 2008.

Type
Biotech
Groups
Approved
Biologic Classification
Protein Based Therapies
Haematopoietic growth factors
Protein Chemical Formula
C2634H4086N722O790S18
Protein Average Weight
59000.0 Da
Sequences
>Thrombopoietin receptor binding domain amino acid sequence 
IEGPTLRQWLAARA
>Amino acid sequence for Fc fusion compound
MDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYV
DGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKA
KGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLD
SDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGKGGGGGIEGPTLR
QWLAARAGGGGGGGGIEGPTLRQWLAARA
Download FASTA Format
Synonyms
Not Available
External IDs
  • AMG 531
  • AMG-531

Pharmacology

Indication

Treatment of chronic immune thrombocytopenic purpura.

Associated Conditions
Contraindications & Blackbox Warnings
Learn about our commercial Contraindications & Blackbox Warnings data.
Learn More
Pharmacodynamics

Responses to platelet increase varies between patients thus indicating a need for individualization of dose. However, a dose dependent-increase in platelet counts have been observed in clinical trials. Does not affect platelet destruction.

Mechanism of action

Romiplostim is a thrombopoietin receptor agonist that activates intracellular transcriptional pathways via c-Mpl to increase production of platelets. It also works similarly to thrombopoietin (TPO), an endogenous glycoprotein hormone that regulates the production of platelets in the bone marrow.

TargetActionsOrganism
AThrombopoietin receptor
agonist
Humans
Absorption

Cmax, healthy volunteers, subQ = 24-36 hours; Cmax, immune thrombocytopenia patients, subQ = 7-50 hours (median = 14 hours). Not affected by age, weight, or gender. Accumulation does not occur after six weekly doses of 3 mcg/kg romiplostim.

Volume of distribution

In healthy volunteers, non-linear decrease in Vd with increase IV dose of romiplostim which indicates saturation of c-Mpl receptors. Vd, 0.3 μg/kg = 122 mL/kg Vd, 10 μg/kg = 48.2 mL/kg

Protein binding
Not Available
Metabolism
Not Available
Route of elimination

Renal clearance (more dominant mode of clearance as dose increases) and
binding to c-Mpl receptors (dominant mode of clearance at low doses)

Half-life

Immune thrombocytopenia patients, subQ = 3.5 days (median) (range 1-34 days)

Clearance
Not Available
Adverse Effects
Learn about our commercial Adverse Effects data.
Learn More
Toxicity

The most common adverse reactions (≥ 5% higher patient incidence in Nplate versus placebo) are arthralgia, dizziness, insomnia, myalgia, pain in extremity, abdominal pain, shoulder pain, dyspepsia, and paresthesia. Headache was the most commonly reported adverse reaction that did not occur at ≥ 5% higher patient incidence in Nplate versus placebo. LD50 = 980 mg/kg.

Affected organisms
  • Humans and other mammals
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
DrugInteraction
CyclophosphamideThe risk or severity of pulmonary toxicity can be increased when Romiplostim is combined with Cyclophosphamide.
VinblastineThe risk or severity of peripheral neuropathy can be increased when Romiplostim is combined with Vinblastine.
VincristineThe risk or severity of peripheral neuropathy can be increased when Romiplostim is combined with Vincristine.
VindesineThe risk or severity of peripheral neuropathy can be increased when Romiplostim is combined with Vindesine.
VinflunineThe risk or severity of peripheral neuropathy can be increased when Romiplostim is combined with Vinflunine.
VinorelbineThe risk or severity of peripheral neuropathy can be increased when Romiplostim is combined with Vinorelbine.
Additional Data Available
  • Extended Description
    Extended Description
    Available for Purchase

    Extended description of the mechanism of action and particular properties of each drug interaction.

    Learn more
  • Severity
    Severity
    Available for Purchase

    A severity rating for each drug interaction, from minor to major.

    Learn more
  • Evidence Level
    Evidence Level
    Available for Purchase

    A rating for the strength of the evidence supporting each drug interaction.

    Learn more
  • Action
    Action
    Available for Purchase

    An effect category for each drug interaction. Know how this interaction affects the subject drug.

    Learn more
Food Interactions
Not Available

Products

Purchasing individual compounds or compound libraries for your research?
Learn More
Brand Name Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing EndRegionImage
NplateInjection, powder, for solution500 μgSubcutaneousAmgen Europe B.V.2009-02-04Not applicableEU flag
NplateInjection, powder, for solution500 μgSubcutaneousAmgen Europe B.V.2009-02-04Not applicableEU flag
NplatePowder, for solution500 mcgSubcutaneousAmgen2009-04-15Not applicableCanada flag
NplatePowder, for solution250 mcgSubcutaneousAmgen2009-04-15Not applicableCanada flag
NplateInjection, powder, for solution250 μgSubcutaneousAmgen Europe B.V.2009-02-04Not applicableEU flag
NplateInjection, powder, lyophilized, for solution500 ug/1mLSubcutaneousAMGEN INC2008-08-25Not applicableUS flag
NplateInjection, powder, for solution250 μgSubcutaneousAmgen Europe B.V.2009-02-04Not applicableEU flag
NplateInjection, powder, for solution250 μgSubcutaneousAmgen Europe B.V.2009-02-04Not applicableEU flag
NplateInjection, powder, lyophilized, for solution125 ug/0.25mLSubcutaneousAMGEN INC2019-08-02Not applicableUS flag
NplateInjection, powder, for solution500 μgSubcutaneousAmgen Europe B.V.2009-02-04Not applicableEU flag
Additional Data Available
  • Application Number
    Application Number
    Available for Purchase

    A unique ID assigned by the FDA when a product is submitted for approval by the labeller.

    Learn more
  • Product Code
    Product Code
    Available for Purchase

    A governmentally-recognized ID which uniquely identifies the product within its regulatory market.

    Learn more

Categories

ATC Codes
B02BX04 — Romiplostim
Drug Categories
Chemical TaxonomyProvided by Classyfire
Description
Not Available
Kingdom
Organic Compounds
Super Class
Organic Acids
Class
Carboxylic Acids and Derivatives
Sub Class
Amino Acids, Peptides, and Analogues
Direct Parent
Peptides
Alternative Parents
Not Available
Substituents
Not Available
Molecular Framework
Not Available
External Descriptors
Not Available

Chemical Identifiers

UNII
GN5XU2DXKV
CAS number
267639-76-9

References

General References
  1. Kumagai Y, Fujita T, Ozaki M, Sahashi K, Ohkura M, Ohtsu T, Arai Y, Sonehara Y, Nichol JL: Pharmacodynamics and pharmacokinetics of AMG 531, a thrombopoiesis-stimulating peptibody, in healthy Japanese subjects: a randomized, placebo-controlled study. J Clin Pharmacol. 2007 Dec;47(12):1489-97. Epub 2007 Oct 9. [PubMed:17925591]
  2. Rice L: Drug evaluation: AMG-531 for the treatment of thrombocytopenias. Curr Opin Investig Drugs. 2006 Sep;7(9):834-41. [PubMed:17002262]
  3. Keating GM: Romiplostim: a review of its use in immune thrombocytopenia. Drugs. 2012 Feb 12;72(3):415-35. doi: 10.2165/11208260-000000000-00000. [PubMed:22316355]
  4. Link [Link]
KEGG Drug
D08990
PubChem Substance
347910087
RxNav
805452
ChEMBL
CHEMBL1201832
RxList
RxList Drug Page
Drugs.com
Drugs.com Drug Page
Wikipedia
Romiplostim
AHFS Codes
  • 20:16.00 — Hematopoietic Agents
FDA label
Download (232 KB)
MSDS
Download (479 KB)

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
4CompletedTreatmentIdiopathic Thrombocytopenic Purpura / Thrombocytopenia1
4CompletedTreatmentImmune Thrombocytopenia1
3CompletedSupportive CareThrombocytopenia in Pediatric Subjects With Immune Idiopathic Thrombocytopenic Purpura ITP1
3CompletedTreatmentIdiopathic Thrombocytopenic Purpura1
3CompletedTreatmentIdiopathic Thrombocytopenic Purpura / Immune Thrombocytopenia / Thrombocytopenia / Thrombocytopenia in Pediatric Subjects With Immune (Idiopathic) Thrombocytopenic Purpura (ITP) / Thrombocytopenia in Subjects With Immune (Idiopathic) Thrombocytopenic Purpura (ITP) / Thrombocytopenic Purpura1
3CompletedTreatmentIdiopathic Thrombocytopenic Purpura / Thrombocytopenia3
3CompletedTreatmentIdiopathic Thrombocytopenic Purpura / Thrombocytopenia / Thrombocytopenia in Subjects With Immune (Idiopathic) Thrombocytopenic Purpura (ITP) / Thrombocytopenic Purpura1
3CompletedTreatmentIdiopathic Thrombocytopenic Purpura / Thrombocytopenia / Thrombocytopenic Purpura1
3CompletedTreatmentImmune Thrombocytopenia2
3RecruitingTreatmentChemotherapy-Induced Thrombocytopenia2

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
FormRouteStrength
Injection, powder, for solutionCutaneous125 MCG
Injection, powder, for solutionCutaneous250 MCG
Injection, powder, for solutionCutaneous500 MCG
Injection, powder, for solutionSubcutaneous250 MCG
Injection, powder, for solutionSubcutaneous250 μg
Injection, powder, for solutionSubcutaneous500 MCG
Injection, powder, for solutionSubcutaneous500 μg
Injection, powder, lyophilized, for solutionSubcutaneous125 ug/0.25mL
Injection, powder, lyophilized, for solutionSubcutaneous250 ug/0.5mL
Injection, powder, lyophilized, for solutionSubcutaneous500 ug/1mL
Powder, for solutionSubcutaneous250 mcg
Powder, for solutionSubcutaneous500 mcg
Injection, powder, lyophilized, for solutionSubcutaneous250 mcg
Injection, powder, for solution250 mcg
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
Not Available

Targets

Kind
Protein
Organism
Humans
Pharmacological action
Yes
Actions
Agonist
General Function
Transmembrane signaling receptor activity
Specific Function
Receptor for thrombopoietin. May represent a regulatory molecule specific for TPO-R-dependent immune responses.
Gene Name
MPL
Uniprot ID
P40238
Uniprot Name
Thrombopoietin receptor
Molecular Weight
71244.08 Da
References
  1. Krzyzanski W, Sutjandra L, Perez-Ruixo JJ, Sloey B, Chow AT, Wang YM: Pharmacokinetic and pharmacodynamic modeling of romiplostim in animals. Pharm Res. 2013 Mar;30(3):655-69. doi: 10.1007/s11095-012-0894-2. Epub 2012 Dec 19. [PubMed:23250851]

Drug created on November 18, 2007 11:23 / Updated on November 23, 2020 09:08

Logo pink
Are you a
new drug developer?
Contact us to learn more about our customized products and solutions.
Logo pink
Stay in the know!
As part of our commitment to providing the most up-to-date drug information, we will be releasing #DrugBankUpdates with our newly added curated drug pages.
#DrugBankUpdates